期刊文献+

甲磺酸达比加群酯的合成 被引量:5

Synthesis of dabigatran etexilate mesylate
原文传递
导出
摘要 目的:研究和改进甲磺酸达比加群酯的合成工艺。方法:以4-甲氨基-3-硝基苯甲酸(2)和3-(吡啶-2-基氨基)丙酸乙酯(3)为原料,经酰氯化、酰胺化、中和成盐和还原制得重要中间体3-[[3-氨基-4-(甲氨基)苯甲酰基](吡啶-2-基)氨基]丙酸乙酯(5)。5再与N-(4-氰基苯基)甘氨酸经酰胺化、闭环、中和成盐、成脒、酰化,进而与甲磺酸成盐制得甲磺酸达比加群酯。结果:中间体及目标化合物经质谱、核磁共振谱、红外光谱等确证,整个工艺的总收率为33.9%。结论:本路线操作简便、成本较低、条件温和、步骤少,适合工业化生产。 Objective: To study and improve the synthesis proccess of dabigatran etexilate mesylate. Methods : The intermediate ethyl 3- [ [ 3-amino-4- ( methylamino ) benzoyl ] ( pyridin-2-yl ) amino ] -propanoate ( 5 ) was prepared from 4-methyl amino-3-nitrobenzoie acid (2) and ethyl 3-(pyridin-2-ylamino) propanoate (3) by chlorination, amidation, neutralization and reduction. Dabigatran etexilate mesylate was synthesized from 5 and (4-cyanophenyl) glyeine by amidation, eyelization, neutralization, amidination, aeylation and salifieation with methane sulfonie acid. Results: The structures of intermediates and target compound were identified by MS and ~H-NMR. The overall yield was 33.9%. Conclusion: This improved method can be used in industrial manufacturing with the advantage of simpler purifying operation, lower cost and mild condition.
出处 《中国新药杂志》 CAS CSCD 北大核心 2012年第1期88-91,共4页 Chinese Journal of New Drugs
基金 江苏省海洋资源开发研究院科技开放基金(JSIMR09B03)
关键词 甲磺酸达比加群酯 抗凝血药 合成 dabigatran etexilate mesylate anticoagulant synthesis
  • 相关文献

参考文献5

二级参考文献40

  • 1张竹霞,吕荣文,张珂珂,高昆玉.水合肼还原芳硝基物的研究[J].精细化工,2001,18(4):239-242. 被引量:54
  • 2郑淑玲,赵增国,张红艳.2-氯吡啶氮氧化物的合成方法研究[J].天津师范大学学报(自然科学版),2006,26(1):9-11. 被引量:5
  • 3聂丽娟,段巨龙,王歌云,李俶,秦中.芳香族硝基化合物催化氢化催化剂Cu-Re_mO_n/SiO_2的放大试验研究[J].精细化工,2006,23(7):654-656. 被引量:4
  • 4Johnstone R A W,Wilby A H,Entwistle I D. Chem Rev[J] ,1985,85(2) :129.
  • 5Lauwiner M, Rys P, Wissmann J. Appl Catal A : Gen [ J ], 1998,172 ( 1 ) - 141.
  • 6Benz M,Kraan A M,Prins R. Appl Catal A:Gen[J] ,1998,172(1) :149.
  • 7Kumbhar P S, Sanchez-Valente J, Millet J M, Figueras F. J Catal[J].,2000,191 (2) :467.
  • 8Kumarraja M, Pitchumani K. Appl Catal A : Gen [ J ], 2004,265 ( 2 ) : 135.
  • 9WANG Li-Min(王利民),TIAN He(田禾).New Methods for Fine Organic Synthesis(精细有机合成新方法)[M].Beijing(北京):Chemical Industry Press(化学工业出版社),2004:26.
  • 10Ren P D,Pan S F,Dong T W,Wu S H. Synth Commun[J] ,1996,26(21 ) :3 903.

共引文献107

同被引文献36

  • 1Lee W M,Larrey D,Olsson R,et al.Hepatic findings in long-term clinical trials ofximelagatran.Drug Saf,2005,28(4):351-370.
  • 2Blech S,Ebner T,Ludwig-Schwellinger E,et al.The metabolism and disposition of the oral direct thrombin inhibitor,dabigatran,in humans.Drug MetabDispos,2008,36(2):386-399.
  • 3Wienen W,Stassen J M,Priepke H,et al.In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug,dabig,atran etexilate.Thromb Haemost,2007,98(1):155-162.
  • 4Serra M J,Duran L E,et al.Dabigatran etexilate and related substances,processes and compositions,and use of the substances as reference standards and markers.EP,2522662(A1)[P].2011-05-11.
  • 5Hauel NH,Nar H,Priepke H,et al.Structure-based design of novel potent nonpeptide thrombin inhibitors[J].J Med Chem,2002,45(9):1757-1766.
  • 6Jirman j,Richter J,Lustig P.A method for the manufacture of dabigatran.WO,2009111997(A1)[P].2008-03-14.
  • 7Segade R A,Pasto A M.Process of preparation of a thrombin specific inhibitor.WO,2012004396(A2)[P].2010-07-09.
  • 8Zentiva K S,Lustig P,Jirman J.A method for the preparation of dabigatran and its intermediates.WO,2010045900(A1)[P].2008-10-24.
  • 9Satyanarayana R M,Nagaraju C,Thirumalai R S,et al.Process for the preparation of benzimidazole derivatives and its salts.WO,2012077136(A2)[P].2011-12-07.
  • 10Kiraly I,Szabo T,Simig G,et al.Process for the manufcture of dabigatran etexilate and inermediates thereof.WO,2012153158(A1)[P].2011-05-11.

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部